Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Australia: ResApp plans new cough trial

Shares in ResApp Health jumped more than 28% earlier this week after the investigators of the group’s clinical trial confirmed that their study was not an accurate or reliable evaluation of ResApp’s algorithms. The release of the initial trials caused shares in the Perth-based digital healthcare operator that focuses on respiratory diseases to crash 77% after they showed significant problems with its main product.

“Having completed a review with all relevant parties it is clear that the first US study was not a reliable evaluation of ResApp’s algorithms and that the top line results do not reflect the actual performance of ResApp’s technology,” said ResApp CEO and managing director Tony Keating.

ResApp’s main product is a cough-based diagnostic test that works with a smartphone to analyse the sound of a patient’s cough and to diagnose any underlying conditions.

In that trial, two main problems were found. First, that contrary to instructions and training, a high number of patients were treated before clinical research staff recorded their cough sounds. And second, a high number of recordings were found to contain a second person’s cough sounds or an unacceptable amount of background noise and interference.

ResApp  plans to restart the study  this winter in the US.

To improve the data gathering element of the study, ResApp will be present onsite conducting clinical study team training, reviewing enrolment procedures and verifying data to help ensure that high-quality cough sounds are collected as early as possible during the patient’s hospital visit and prior to any treatment known to affect cough analysis. Every cough sound collected will be quality checked within days of its recording to ensure that all of the data used to subsequently analyse the performance of the algorithm is uncorrupted and high fidelity. An improved audio recording smartphone application incorporating built-in checklists, automated background noise estimation and additional visual aids will be deployed further to support the data collection teams and eliminate inappropriate collection of cough data with background noise contamination.

ResApp’s algorithms have also been modified to reduce the impact of the low frequency electronic interference found in nearly 15% of the previous study recordings.

ResApp plans to broaden its paediatric clinical strategy by reconfiguring its Australian study to support European and Australian regulatory filings directly. Since earlier this year, the Australian paediatric study at Joondalup Hospital has been recruiting patients for double-blind prospective analysis with 230 patients recruited to date. To support regulatory submissions, a team of clinicians will perform adjudication and Curtin University health researchers will provide independent statistical analysis.

ResApp shares closed on Monday at A$0.09 (US$0.07).

Posted on: 06/09/2017 UTC+08:00


News

US-based private equity investment firm TPG Growth has acquired Nova IVI, India’s second largest provider of fertility treatment services.
Online Chinese insurance platform Waterdrop has raised over a billion yuan (US$145 million) in a funding round led by private equity firm Boyu Capital.
The 'Medical Trends Around the World’ report has caught the attention of the Asia-Pacific press with Business World noting that healthcare inflation in Vietnam’s at 14.2% is the highest in Asia.
GT Apeiron Therapeutics a novel biotechnology company, was launched today with the backing of GT Healthcare and associated investors.
Government agency BP Batam (Indonesia) and dClinic have joined forces to establish a private healthcare blockchain in Indonesia.
The Chinese government is to investigate bribery in the country’s healthcare system by analysing payments made by pharmaceutical companies.
Singapore-based Verita Healthcare Group, a provider of preventative and personalised healthcare, has appointed Michael James Kirkwood to its board as an independent non-executive director.
Zuellig Pharma, one of the largest healthcare groups in Asia, has acquired healthtech start-up Klinify, a cloud-based digital medical assistant used by more than 800 doctors in Malaysia.



Analysis

Against the backdrop of a robust healthcare market with positive macro factors, speakers and delegates delved into the opportunities and challenges, and analysed the changing face of the region’s healthcare market
L.E.K. Consulting’s Fabio La Mola tells HealthInvestor Asia about a healthcare market going through major changes – creating significant opportunities for investors in the region.
Sumit Sharma and Matt Zafra, head and principal of health & life sciences, Asia Pacific at Oliver Wyman, look at what we can expect in 2019.
Edwin Tong, senior minister for health, explains how the Ministry of Health in Singapore is supporting the growth in the number of seniors with Alzheimer's.
Penny Wan, regional vice-president and general manager, Japan and APAC, Amgen, writes about the public health challenge of cardiovascular diseases.
French-based international ophthalmic optics company Essilor has signed Letters of Intent with the Royal Government of Bhutan and the Central Monastic Body to strengthen the country’s vision care infrastructure.
April Chang, country manager at Cigna Singapore, argues that wellness programmes at work can lead to reduced absenteeism, higher productivity and increased morale among employees.
Steven Fang understands how to set up a healthcare company. Not only is he chief executive and founder of ASX-listed oncology company Invitrocue, he was also the founder of Singapore-based Cordlife Group, a healthcare company which provides cord blood and cord lining banking services.


Podcasts

HealthInvestor Asia twitter feed